FDA Shares Tips for Speedier Gene-Editing Therapies
Published Date: 6/3/2026
Notice
Summary
The FDA just dropped a draft guide to help companies making gene therapy products that use genome editing. It shows how to use what’s already known to speed up development and get safer, smarter treatments to patients faster. If you’re in this field, send your feedback by September 1, 2026, so your voice shapes the final rules—saving time and money down the road!
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Use Prior Knowledge to Speed Gene Therapies
The FDA released a draft guidance that tells sponsors how to use prior knowledge from chemistry, manufacturing, nonclinical, and clinical data to increase review efficiency and accelerate development of human gene therapy products that incorporate genome editing. The agency says this approach may be especially helpful for programs targeting rare diseases. Submit comments by September 1, 2026.
Guidance May Apply Beyond Genome Editing
The draft guidance says some recommendations, when finalized, may also apply to other cell and gene therapy products such as adeno-associated viral vectors, nanoparticle-based gene therapy products, and ex vivo-modified cell-based gene therapies that do not incorporate genome editing, though additional considerations may apply based on the specific product and manufacturing process. Stakeholders can comment on the draft by September 1, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073 — Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-14573 — Food Standards of Identity Modernization; Pasteurized Orange Juice
The FDA is updating the rules for pasteurized orange juice by lowering the minimum sugar content and allowing up to 15% of a new type of citrus juice. This change helps juice makers, especially in Florida, keep up with modern practices without raising costs. The new rules kick in on August 19, 2026, giving producers time to adjust.
2026-14438 — Agency Information Collection Activities; Proposed Collection; Comment Request; Infant Formula Requirements
The FDA wants your thoughts on how they collect info about infant formula rules, like labeling, quality checks, and recordkeeping. This affects infant formula makers who must follow these rules and use a new electronic form to report info. You’ve got until September 15, 2026, to share your comments—no cost changes yet, just a chance to improve how info is gathered!
2026-14441 — Agency Information Collection Activities; Proposed Collection; Comment Request; Accreditation Scheme for Conformity Assessment Program
The FDA wants your thoughts on a plan to improve how they check if medical products meet safety rules. This affects companies making medical devices and could change how they prove their products are safe. You’ve got until September 15, 2026, to share your ideas—no cost changes yet, just a chance to help shape the process!
2026-14436 — Agency Information Collection Activities; Proposed Collection; Comment Request; Medical Devices; Voluntary Improvement Program
The FDA wants your thoughts on a new plan to collect info from medical device makers who join a Voluntary Improvement Program. This program aims to help companies improve their devices without extra paperwork stress. If you’re involved in making or managing medical devices, you’ve got until September 15, 2026, to share your feedback—no fees, just your voice!
Previous / Next Documents
Previous: 2026-11051 — Notice of Matching Fund Opportunity for Ocean and Coastal Mapping and Request for Partnership Proposals
NOAA is teaming up with non-Federal groups to map oceans, coasts, and the Great Lakes by matching their funds for cool mapping projects. If you’re interested, get ready to apply by October 16, 2026, and join info sessions in August and September. This is a great chance to share costs, get expert help, and make waves in mapping with money moving in 2027 and work kicking off in 2028!
Next: 2026-11055 — Hermit's Peak/Calf Canyon Fire Assistance
If you were affected by the Hermit's Peak/Calf Canyon fires and already filed a claim for help, you have until August 3, 2026, to ask FEMA to reopen your claim if you’ve had more losses or need extra support. This is your chance to get more assistance for rebuilding or repairs. Don’t miss the deadline to make sure you get all the help you deserve!